uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

Core Viewpoint - A securities class action lawsuit has been filed against uniQure N.V. for failing to disclose material information regarding its drug candidate AMT-130, leading to significant stock price decline during the class period [1][3][4]. Group 1: Lawsuit Details - Investors have until April 13, 2026, to file lead plaintiff applications if they purchased shares between September 24, 2025, and October 31, 2025 [1]. - The lawsuit alleges that uniQure and certain executives violated federal securities laws by not disclosing critical information during the class period [3]. - The case is identified as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124 [5]. Group 2: Company Performance and Impact - During the class period, uniQure indicated a high likelihood of receiving accelerated FDA approval for AMT-130, which was later contradicted by the FDA's assessment [4]. - Following the FDA's announcement on November 3, 2025, uniQure's stock price fell by $33.40, or over 49%, from $67.69 to $34.29 per share [4].